Company Overview
Snapshot
Founded in April 2020 by Eyal Afergan, Tamir Tuller, and Arie Abo, Imagindairy operates with 11–50 employees. The company has raised $33.46 million across 5 funding rounds from 13 investors. In January 2024, Imagindairy acquired industrial-scale precision fermentation production lines, signaling a move towards mass-market adoption of its animal-free whey protein.
Business overview
Imagindairy is a food technology company focused on revolutionizing the dairy industry by producing sustainable, animal-free dairy proteins. Utilizing precision fermentation, the company's core technology leverages advanced computational and molecular biology to amplify protein expression, creating cost-effective processes. These proteins are designed to replicate the flavor, mouthfeel, functionality, and nutritional properties of bovine-sourced dairy, enabling the creation of cholesterol-free, lactose-free, and hormone-free dairy products. Imagindairy primarily serves the food industry, operating within the Agriculture & Food Technologies sector, specifically in Food Tech and Novel Food & Ingredients, with a focus on dairy alternatives.
Strategic signal
In November 2024, Imagindairy received regulatory approval from the Israeli Ministry of Health to market its factory-produced beta-lactoglobulin (BLG) in Israel, following earlier FDA approval for the U.S. market. This dual regulatory clearance is a strong signal of market readiness and validation for its precision fermentation technology, positioning Imagindairy to expand its commercialization efforts and engage with food companies in key markets.
Log in to access full profile ›Company Intelligence Q&A
- What significant regulatory approvals has Imagindairy recently secured?
- In November 2024, Imagindairy received regulatory approval from the Israeli Ministry of Health to market its animal-free beta-lactoglobulin (BLG) in Israel. This followed an earlier FDA approval for the U.S. market in January 2024, affirming the GRAS (Generally Recognized as Safe) status of its whey protein.
- What was a key strategic development for Imagindairy in early 2024?
- In January 2024, Imagindairy acquired industrial-scale precision fermentation production lines. This strategic move is intended to support mass-market adoption of its animal-free whey protein and facilitate the launch of products containing its ingredients in the US market.
- Which investors participated in Imagindairy's Seed round extension in May 2022?
- Imagindairy secured an extension to its Seed round in May 2022, with Target Global leading the investment. Strauss Investments and Entrée Capital also participated in this round.
- What was Imagindairy's involvement with the World Economic Forum in 2024?
- In July 2024, Imagindairy was selected by the World Economic Forum as one of the 100 Technology Pioneers for its 2024 cohort. This recognition highlights the company's innovative use of AI and its potential to develop solutions across various industries.
- What is Imagindairy's primary technological approach?
- Imagindairy utilizes precision fermentation technology to produce animal-free dairy proteins. This approach involves advanced computational and molecular biology to amplify protein expression, aiming to create dairy products that are identical to those from bovine sources but without animal involvement.